The UK GLP-1 Grey Market: 135 Companies, 1 Death, and Why the Safe Path Matters
We audited every UK company with 'peptide' in its name on Companies House. 98 are brand new with no track record, none of the credible ones supply GLP-1, and one woman has already died. Here's what patients need to know — and the safe alternative.
In May 2025, a 53-year-old woman in the UK died after receiving illicit semaglutide injections at a beauty salon. Her two daughters went public to warn other women. Five months later, the MHRA dismantled an illegal manufacturing facility in Northampton, seizing more than 2,000 pre-filled pens of tirzepatide and retatrutide — the latter a drug still in clinical trials and not legally available anywhere in the world. As of January 2025, 82 deaths had been reported to the MHRA's Yellow Card scheme in connection with GLP-1 medicines.
These are not isolated incidents. They are the visible tip of a market that has exploded in the United Kingdom over the last twelve months — a grey market in research-grade peptides, sold to consumers under "research only" disclaimers, sourced largely from China, and operated by companies that did not exist a year ago.
We mapped this market. The findings should change how every UK patient thinks about where their GLP-1 medicine comes from.
What we did
We pulled the full Companies House register for every company with "peptide" or "peptides" in its name. We classified each one by status, age, and whether it had filed accounts. We then checked the websites and product catalogues of every credible supplier, and cross-referenced the regulatory record. The result is the most complete picture available of the UK peptide industry as it stands today.
Here is what the data shows.
Finding 1: The peptide gold rush is real, and it is brand new
There are 135 companies on the UK register with "peptide" or "peptides" in their name. Of these:
That sounds like a substantial industry. It is not. Of those 106 active companies, only 8 are old enough (more than 21 months since incorporation) to have hit their first statutory accounts deadline. The other 98 — that is 92% of the active register — were incorporated within the last twelve months.
Almost 80 of them were incorporated in the last six months alone. Two were incorporated on the day we ran this audit, 29 April 2026. None of the 98 has ever filed a set of accounts. None has any verifiable trading history. None has been audited by HMRC. None has demonstrated a manufacturing capability, a quality-control infrastructure, a banking relationship that survived more than a season, or anything else that would normally indicate a real business.
This is what a gold rush looks like in Companies House data — a flood of cheap shell registrations chasing a sudden consumer-demand wave.
Finding 2: Of the eight companies old enough to have a track record, exactly zero supply GLP-1
We checked the websites and product catalogues of every one of the eight filing-eligible companies. The results are striking:
| Company | Founded | Sells GLP-1? |
|---|---|---|
| Peptide Protein Research Ltd | 1999 | No GLP-1 catalogue product |
| Cambridge Peptides Ltd | 2004 | Explicitly refuses |
| Cupid Peptide Company Ltd | 2012 | No (cell-permeable peptide research tools) |
| Peptide Groove LLP | 2013 | Unclear |
| Origin Peptides Ltd | 2018 | Indirect mention, no product |
| Peptide Pets Ltd | 2022 | No |
| Triple Helical Peptides Ltd | 2023 | No (collagen-mimetic research) |
| Taiwan Oyi Peptide Co Ltd | 2023 | Dormant company |
The most telling case is Cambridge Peptides Ltd, the closest thing the UK has to an established peptide synthesis house. Their website carries a clear disclaimer: *"Our peptides are strictly for scientific research and industrial applications. We do not supply peptides for personal use, including bodybuilding, weight loss, skincare etc."*
The credible UK peptide industry has firewalled itself out of the GLP-1 / weight-loss market. They will not touch it. The 98 newly registered shell companies are filling that void.
Finding 3: Where the drugs actually come from
A peer-reviewed 2024 paper in *Drug Use and Misuse* — "Made in China: The international supply of illicit Semaglutide and weight-loss medicines online" — laid out the supply chain in detail. Independent investigations by the National Association of Boards of Pharmacy in the United States and Partnership for Safe Medicines confirmed the same picture. The grey-market funnel works like this:
Despite the disclaimers, the consumer intent is unambiguous. We checked one popular UK research-peptide retailer that organises its inventory under category headings such as "Fat Loss," "Muscle Growth," and "Anti-Aging." Tirzepatide vials retail at around £43; retatrutide at around £60. By comparison, a month of branded Wegovy on UK private prescription is £150–£250. The grey market exists because the legal market has priced itself out of reach for most people who want access.
Finding 4: There is no easy way for a consumer to verify what is in the vial
We thought hard about whether a customer can protect themselves with a home test. The honest answer is: not really.
Peptides like semaglutide and tirzepatide are 30–40 amino acid molecules with unusual modifications. Telling them apart from other peptides — or from saline — requires mass spectrometry or high-performance liquid chromatography. These are laboratory techniques that cost £50–£200 per sample at a third-party lab and take 1–2 weeks for results. Consumer-grade lateral-flow tests of the kind that exist for pregnancy or COVID do not exist for sema/tirz/reta. The reagents and antibodies needed to make one are available in research labs, but no one has commercialised a consumer in-vitro diagnostic.
What a consumer can do at home — visual inspection, a pH strip, a microscope photo to compare consistency, a symptom log, or continuous glucose monitoring as a downstream proxy — catches gross failures only. A vial that contains saline instead of semaglutide can sometimes be spotted. A vial that contains 67% of the labelled dose, or a near-relative peptide that the manufacturer substituted, will look identical to the real product.
This matters because the actual harms in this market come from exactly those subtle failures.
Finding 5: Documented harm is no longer hypothetical
The case literature on grey-market GLP-1 use is now substantial enough to draw a clear pattern. Four distinct failure modes have caused documented hospitalisations and deaths.
Massive dose errors from reconstitution. Grey-market vials are sold in raw milligrams of API. The user must reconstitute the powder with bacteriostatic water, draw the correct volume into an insulin syringe, and inject. The maths is unforgiving. Published cases include a 53-year-old man who injected 2 mg instead of 0.1 mg — a 20-fold overdose — and was hospitalised; a 45-year-old woman who injected 2.4 mg instead of 0.25 mg; and a severe case in which a self-administered overdose caused acute kidney injury, gastrointestinal bleeding, ischaemic necrosis of the upper gastrointestinal tract, and biliary pancreatitis. None of these patients had any source of clinical guidance.
Counterfeit content. Three counterfeit batches of branded Ozempic infiltrated the legitimate UK supply chain in October 2023, identified by Novo Nordisk and the MHRA. Some contained insulin instead of semaglutide, leading to severe hypoglycaemia. The FDA's adverse-event reporting system has logged 42 reports of counterfeit semaglutide, 28 classified "serious," with outcomes including deaths.
Sterility failures. Non-sterile manufacturing causes injection-site abscesses, bacteraemia, and sepsis. The Northampton raid suggested a level of sanitation in domestic UK clandestine manufacturing that no one would tolerate in a regulated pharmacy.
No medical screening. Even a perfectly genuine, perfectly dosed vial of semaglutide is dangerous in the wrong patient. It is contraindicated in family history of medullary thyroid carcinoma, severe gastroparesis, gallbladder disease, and pregnancy. Drug interactions with oral contraceptives reduce contraceptive efficacy. The MHRA's own Drug Safety Update has flagged misuse risk repeatedly. None of these checks happen when a patient orders a £43 vial off a Shopify store.
The real-world impact in the UK alone, in 2025: a beauty-salon death, the Northampton manufacturing raid, an MHRA investigation into peptide clinics for unlawful health claims, and a Yellow Card system actively recruiting hospitalised pancreatitis cases.
Why this market exists
It is worth being honest about the demand side. The UK has no compounding pharmacy infrastructure of the kind that exists in the United States under FDA 503A and 503B regulations. Branded GLP-1s on private prescription cost £150–£250 per month. NHS prescribing is restricted by BMI thresholds and multi-month waitlists. Consumers who fall outside the eligibility window — or who simply cannot wait — face a binary choice: pay private clinic prices that compound to thousands of pounds a year, or buy off the grey market at a tenth of the cost.
The grey market exists because the legal market does not serve them. That demand is not going to disappear. The MHRA crackdown will reduce supply, but it will also push the market further underground and further beyond any consumer's ability to verify what they are receiving.
The safe path
This is the entire reason Magistra exists. Our model is built on three things, in this order:
1. A doctor first, every time. Every Magistra patient is matched with a verified, licensed physician before any prescription is written. The doctor reviews your medical history, screens for contraindications, decides whether GLP-1 medication is appropriate for you, sets the starting dose, and supervises the titration. No vial is ordered, no website is browsed, until that consultation has happened. There is no "research-only" loophole in our model. There is no anonymous transaction. There is a doctor whose name, credentials, and licensing body you can verify, and who is professionally accountable for the prescription they write.
2. The world's most comprehensive GLP-1 outcomes database, powering personalised predictions. Magistra maintains the largest known database of GLP-1 safety and efficacy data — drawn from PubMed, FDA FAERS, ClinicalTrials.gov, regulatory reports across multiple jurisdictions, and patient-contributed real-world experiences. We use it to give every patient a personalised forecast of their likely weight trajectory, side-effect risk, muscle-preservation profile, and discontinuation outcomes. The methodology is publication-grade — TRIPOD-compliant, with calibration and bias adjustments — and the underlying data is publicly available through our research API. Our models are open. Our methodology is documented. You and your doctor see the same evidence, and you make the decision together.
3. Live intelligence on the global supply chain. Magistra tracks GLP-1 supply, demand, and international trade across 51 countries — patent expiries, licensed generic launches, regulator-approved manufacturers, pricing across jurisdictions, supply disruptions, and emerging access pathways. This is not a sales catalogue. It is a transparent, continuously updated picture of where the legitimate global supply is and how it is changing, so that your doctor can prescribe what is genuinely available, properly licensed, and properly cold-chain-managed for your country. Our GLP-1 Economics hub is the public-facing window into this work.
These three things — a doctor, a database, and supply transparency — are what make safe access actually possible. None of them exists in the grey market. All three are why we built Magistra.
What you should do
If you are considering GLP-1 medication for weight management, the questions that matter are simple:
Magistra is built to answer all four questions on your behalf. The grey market is built to avoid them.
Get matched with a doctor — and see your personalised forecast
Two ways to start with Magistra today:
Already on a GLP-1 medication and want to track your progress? Join the waitlist and we'll notify you when our patient-tracking and supply-verification tools open in your country.
This article is educational and based on publicly available data from Companies House (UK), the MHRA, the FDA, the WHO, and peer-reviewed medical literature. Sources include: Companies House register (April 2026), MHRA Drug Safety Updates, the Partnership for Safe Medicines (October 2025), "Made in China: The international supply of illicit Semaglutide and weight-loss medicines online" (Drug Use and Misuse, 2024), the FDA Adverse Event Reporting System, and case reports in peer-reviewed clinical toxicology journals (PubMed PMID 38470137, 40232990, 40849680). Magistra does not provide medical advice. Always consult a licensed healthcare provider before starting or changing any medication.
Ready to start?
Complete a short questionnaire and discover if a personalised programme is right for you.
Get Started